Table 4.
Univariate and multivariate Cox regression for progression-free and overall survival
| Progression-free survival | Univariate | Multivariate (1)a | Multivariate (2)b | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
| Sex (men vs. women) | 1.165 (0.842–1.612) | 0.357 | ||||
| Symptom stage (B vs. A) | 2.357 (1.630–3.407) | < 0.001 | 1.555 (1.059–2.282) | 0.024 | 1.556 (1.066–2.273) | 0.022 |
| NCCN-IPI | ||||||
| Low to low-intermediate | Ref. | Ref. | Ref. | |||
| High-intermediate | 5.476 (3.468–8.645) | < 0.001 | 4.754 (2.965–7.622) | < 0.001 | 4.707 (2.939–7.537) | < 0.001 |
| High | 11.289 (6.858–18.584) | < 0.001 | 8.190 (4.694–14.290) | < 0.001 | 8.168 (4.732–14.101) | < 0.001 |
| Bone marrow involvement (yes vs. no) | 2.387 (1.591–3.579) | < 0.001 | 1.109 (0.721–1.704) | 0.637 | 1.111 (0.724–1.706) | 0.630 |
| Bulky disease (yes vs. no) | 1.108 (0.745–1.646) | 0.613 | ||||
| Cell-of-origin | ||||||
| GCB | Ref. | |||||
| Non-GCB | 1.086 (0.679–1.738) | 0.730 | ||||
| Unknown | 0.975 (0.592–1.605) | 0.921 | ||||
| L3-SMI (low vs. high) | 1.834 (1.322–2.544) | < 0.001 | 1.561 (1.113–2.189) | 0.010 | ||
| CONUT | ||||||
| Normal to mild | Ref. | Ref. | ||||
| Moderate to severe | 2.973 (2.142–4.126) | < 0.001 | 1.499 (1.040–2.159) | 0.030 | ||
| CONUT-SMI category | ||||||
| Group A | Ref. | Ref. | ||||
| Group B | 2.231 (1.535–3.243) | < 0.001 | 1.632 (1.106–2.407) | 0.014 | ||
| Group C | 5.091 (3.212–8.068) | < 0.001 | 2.314 (1.392–3.844) | 0.001 | ||
| Overall survival | Univariate | Multivariate | ||||
| HR (95% CI) | P | HR (95% CI) | P | |||
| Sex (men vs. women) | 1.166 (0.835–1.629) | 0.368 | ||||
| Symptom stage (B vs. A) | 2.279 (1.561–3.325) | < 0.001 | 1.556 (1.051–2.302) | 0.027 | 1.544 (1.048–2.276) | 0.028 |
| NCCN-IPI | ||||||
| Low to low-intermediate | Ref. | Ref. | Ref. | |||
| High-intermediate | 4.932 (3.097–7.854) | < 0.001 | 4.369 (2.703–7.062) | < 0.001 | 4.266 (2.644–6.883) | < 0.001 |
| High | 12.775 (7.702–21.188) | < 0.001 | 9.687 (5.510–17.030) | < 0.001 | 9.486 (5.460–16.480) | < 0.001 |
| Bone marrow involvement (yes vs. no) | 2.264 (1.480–3.462) | < 0.001 | 1.030 (0.655–1.619) | 0.899 | 1.037 (0.660–1.630) | 0.875 |
| Bulky disease (yes vs. no) | 1.142 (0.763–1.711) | 0.518 | ||||
| Cell-of-Origin | ||||||
| GCB | Ref. | |||||
| Non-GCB | 1.067 (0.653–1.744) | 0.795 | ||||
| Unknown | 0.982 (0.585–1.649) | 0.946 | ||||
| L3-SMI (low vs. high) | 1.925 (1.373–2.699) | < 0.001 | 1.670 (1.178–2.369) | 0.004 | ||
| CONUT | ||||||
| Normal to mild | Ref. | Ref. | ||||
| Moderate to severe | 3.023 (2.159–4.232) | < 0.001 | 1.470 (1.011–2.136) | 0.044 | ||
| CONUT-SMI category | ||||||
| Group A | Ref. | Ref. | ||||
| Group B | 2.333 (1.590–3.423) | < 0.001 | 1.721 (1.157–2.561) | 0.007 | ||
| Group C | 5.430 (3.377–8.733) | < 0.001 | 2.423 (1.436–4.087) | 0.001 | ||
aThe analysis excludes the CONUT + L3-SMI combined model
bNeither the CONUT nor L3-SMI individual models are included in the analysis
HR hazard ratio, 95% CI 95% confidence interval, NCCN-IPI National Comprehensive Cancer Network International Prognostic Index, GCB germinal center B cell-like, SMI skeletal muscle index, CONUT Controlling Nutritional Status